Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis
A live, multi-source view of Vertex Pharmaceuticals Incorporated (VRTX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
Sector: Healthcare · Industry: Biotechnology · United States · 6,400 employees · vrtx.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Vertex Pharmaceuticals Incorporated (VRTX) had a market capitalization of $138.42B, a trailing P/E of 31.8 (forward 25.1) and a beta of 0.32; the shares traded in a 52-week range of $374.17 – $560.25 (38.2% over the year).
- Market cap
- $138.42B
- Enterprise value
- $132.55B
- Trailing P/E
- 31.8
- Forward P/E
- 25.1
- PEG ratio
- 1.70
- Price / book
- 6.83
- EPS (trailing)
- $17.15
- EPS (forward)
- $21.77
- Payout ratio
- 0.0%
- 52-week range
- $374.17 – $560.25
- 52-week change
- 38.2%
- Beta
- 0.32
- Average volume
- 1.5M
- Shares outstanding
- 253.5M
- Short % of float
- 1.85%
- Profit margin
- 35.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Vertex Pharmaceuticals Incorporated (VRTX) last closed at $514.56 (the last completed close before that scan).
Technicals at the scan: RSI 44 (neutral territory), price -4.4% versus its 20-day average, 20-day versus 50-day average spread +5.4%, MACD histogram -5.33.
Sentiment inputs: 93% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 73/100.
Next scheduled company event: in 52 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 1 buy and 2 sells of VRTX; corporate insiders filed 0 buys and 0 sells (3 distinct filers, latest disclosure 2026-09-05). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: David J. Taylor (0B/1S), Tommy Tuberville (0B/1S), Alan Armstrong (1B/0S). Who is trading what
RapidTradeView pick record
VRTX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Vertex Pharmaceuticals Incorporated (VRTX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell VRTX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.